Efficacy and Safety of Ketoprofen Topical Patch 20% in the Treatment of Pain Associated With Shoulder, Elbow or Knee Tendonitis or Bursitis

Record History

See every version on ClinicalTrials.gov ↗

1. Notable Sep 29, 2026 Lead sponsor: APR Applied Pharma Research s.a. to Alkemira SA

   • Eligibility criteria expanded, about 10 words
   • Secondary endpoints: details revised at 1 of 1 entry
2. May 19, 2026 Re-verified, no change to tracked fieldsv5
3. Notable Apr 30, 2026 Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company to APR Applied Pharma Research s.a.v4 Show 7 more changesShow less

   • Sponsor's reason: Sufficient number of subjects accrued to conduct analysis to Sponsor (Endo Pharmaceuticals) decision (business reasons)
   • Enrollment target: estimated 330 to confirmed 381
   • Primary completion date: May 2008 to Mar 10, 2008
   • Study completion date changed from estimate of Oct 2008 to Mar 10, 2008
   • Start date: Jan 2007 to Feb 7, 2007
   • Interventions: Ketoprofen Topical Patch 20% (Drug) to Ketoprofen Topical Patch 20% (Drug), Placebo (Other)
   • Study arms: 0 to 2
4. Stopped Aug 13, 2008 Trial status: Recruiting to Terminated Sponsor's reason: Sufficient number of subjects accrued to conduct analysis

   • Primary completion date: May 2008
   • Study completion date: Oct 2007 to Oct 2008
   • Site details revised

   v3
5. Sep 12, 2007 Re-verified, no change to tracked fieldsv2
6. Jan 24, 2007 Study First Submitted

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.